ArticlePeerJ2018
Evolutionary dynamics of GII.17 norovirus.
Article in PeerJ, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The emergence and evolutionary advantage of the novel epidemic norovirus GII.17 lineage.Archives of virology · 2026Article
- Increase of GII.17 Norovirus Infections During the 2024-2025 Season in Multiple Cities, China.Journal of medical virology · 2026Article
- Appearance and spread of norovirus genotype GII.17 subcluster C2 (Romania-2021 like) in Nizhny Novgorod, Russia, 2021-2023.Archives of virology · 2025Article
- Antigenic structural analysis of bat and human norovirus protruding (P) domains.Journal of virology · 2025Article
- Detection of human noroviruses in sewage by next generation sequencing in Shandong Province, 2019-2021.Virology journal · 2025Article
- Genome characterisation of norovirus GII.P17-GII.17 detected during a large gastroenteritis outbreak in Romania in 2021.Archives of virology · 2023Article
- Article
- Prevalence and Evolution of Noroviruses between 1966 and 2019, Implications for Vaccine Design.Pathogens (Basel, Switzerland) · 2021Article
- Evolutionary Mechanism of Immunological Cross-Reactivity Between Different GII.17 Variants.Frontiers in microbiology · 2021Article
- Molecular evolution of GII.P17-GII.17 norovirus associated with sporadic acute gastroenteritis cases during 2013-2018 in Zhoushan Islands, China.Virus genes · 2020Article
- Molecular and evolutionary characterization of norovirus GII.17 in the northern region of Brazil.BMC infectious diseases · 2019Article
- Review
- Evolutionary Analysis of theFrontiers in microbiology · 2019Article
- Article
- Molecular Evolutionary Analyses of the RNA-Dependent RNA Polymerase Region in Norovirus Genogroup II.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the winter of 2014-2015, a rarely reported norovirus (NoV) genotype GII.17 was found to have increased its frequency in norovirus outbreaks in East Asia, surpassing the GII.4 NoV infections. GII.17 genotype has been detected for over three decades in the world. The aim of this study is to examine the evolutionary dynamics of GII.17 over the last four decades.
methodsNoV GII.17 sequences with complete or nearly complete VP1 were downloaded from GenBank and the phylogenetic analyses were then conducted.
resultsThe maximum likelihood analysis showed that GII.17 genotype could be divided into four different clades (Clades A-D). The strains detected after 2012, which could be the cause of the outbreaks, were separated into Clades C-D with their mean amino acid distance being 4.5%. Bayesian Markov chain Monte Carlo analyses indicated that the rate of nucleotide substitution per sites was 1.68 × 10
conclusionThe novel GII.17 strains that caused outbreaks in 2013-2015 may have two new variants. The evolvement of HBGAs binding site and epitopes in P2 subdomain might contribute to the novel GII.17 strains predominance in some regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.